synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-05 and is reviewed periodically as new material appears.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Further reading == Gupta D, Royet J (2024), "Peptidoglycan Recognition Proteins (PGRPs) and Lysozyme", Reference Module in Life Sciences, Elsevier, doi:10.1016/b978-0-128-24465-4.00100-9, ISBN 978-0-12-809633-8, retrieved 2025-03-01
distillation The process of separating the component substances of a liquid mixture by exploiting differences in the relative volatility of the mixture's components through selective boiling and subsequent condensation. The apparatus used to distill a substance is called a still, and the re-condensed substance yielded by the process is called the distillate.
Maria Atalioti, Chief Inspector, Sovereign Base Areas Police, Cyprus. For services to Policing, Diversity and Inclusion in the Sovereign Base Areas. Elliott Forbes, Deputy Commissioner, Royal Anguilla Police Force. For services to Policing in Anguilla.
== Volunteers == CLSI relies on more than 2,000 volunteers. Volunteers and mentors also collaborate with CLSI's Global Health Partnerships to help establish laboratory quality management systems in resource-limited countries.
Hydromorphone, also known as dihydromorphinone, and sold under the brand name Dilaudid among others, is a morphinan opioid used to treat moderate to severe pain. Typically, long-term use is only recommended for pain due to cancer. It may be used by mouth or by injection into a vein, muscle, or under the skin. Effects generally begin within half an hour and last for up to five hours. A 2016 Cochrane review (updated in 2021) found little difference in benefit between hydromorphone and other opioids for cancer pain. Common side effects include dizziness, euphoria, sleepiness, nausea, itchiness, and constipation. Serious side effects may include abuse, low blood pressure, seizures, respiratory depression, and serotonin syndrome. Rapidly decreasing the dose may result in opioid withdrawal. Generally, use during pregnancy or breastfeeding is not recommended. Hydromorphone exerts its effects by activating opioid receptors, mainly in the brain and spinal cord. Hydromorphone 2 mg IV is equivalent to approximately 10 mg morphine IV. Hydromorphone was patented in 1923. Hydromorphone is made from morphine. Hydromorphone is a therapeutic alternative on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 233rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Sources: en.wikipedia.org
=== Extrapulmonary === Very rarely, the primary site for small-cell carcinoma is outside of the lungs and pleural space; in these cases, it is referred to as extrapulmonary small-cell carcinoma (EPSCC). Outside of the respiratory tract, small-cell carcinoma can appear in the cervix, prostate, liver, pancreas, gastrointestinal tract, or bladder. It is estimated to account for 1,000 new cases a year in the U.S. Histologically similar to small-cell lung cancer, therapies for small-cell lung cancer are usually used to treat EPSCC. First-line treatment is usually with cisplatin and etoposide. In Japan, first-line treatment is shifting to irinotecan and cisplatin. When the primary site is in the skin, it is referred to as a Merkel-cell carcinoma.
Hegseth's former sister-in-law, Danielle, sent an affidavit to senators alleging that he was abusive to his second wife, Samantha, and that he had issues with over-consumption of alcohol. Hegseth denied having a drinking problem and pledged not to drink if confirmed. On January 24, Hegseth was confirmed by the Senate in a 51–50 vote. Every Republican senator, with the exception of Susan Collins, Lisa Murkowski, and Mitch McConnell, voted to confirm him, while every Democratic senator opposed his nomination, leading to a 50–50 vote. Vance cast a tie-breaking vote to confirm Hegseth. His confirmation was threatened by Senator Thom Tillis, who told Senate majority leader John Thune the day before that he would not vote for Hegseth on the basis of his sexual assault allegations. Persuaded by Vance, Tillis expressed support for Hegseth on X minutes before the vote. His confirmation was the second in US history to be decided by a vice president, after Betsy DeVos's confirmation for secretary of education in 2017.
=== Greek life, social clubs, and organizations === Morgan State University has over 20+ fraternity and sorority chapters including the nine National Pan-Hellenic Council (NPHC) organizations, social fellowships, clubs, student government association (SGA), and free purpose recreation spaces.
Currently metopon, which has a DEA ACSCN of 9260, does not have an annual manufacturing quota listed in the Federal Register and the bulk of the research on the drug at this time is taking place in Germany, Switzerland, and Austria.
He narrated the Fulldome production Astronaut (2006), created for the National Space Centre. Around the same time, he also narrated the STV show JetSet (also 2006), a six-part series following the lives of trainee pilots and navigators at RAF Lossiemouth as they undergo a gruelling six-month course learning to fly the Tornado GR4, the RAF's primary attack aircraft. McGregor starred opposite Colin Farrell in the Woody Allen film Cassandra's Dream (2007), and he co-starred with Jim Carrey in I Love You Phillip Morris and appeared in Amelia (both 2009) alongside Hilary Swank. He played "the ghost" – the unnamed main character – in Roman Polanski's political thriller The Ghost Writer (2010). He portrayed Camerlengo Patrick McKenna in Ron Howard's mystery thriller Angels & Demons (also 2009), the film adaptation of Dan Brown's novel of the same name and a sequel to Howard's The Da Vinci Code, co-starring Tom Hanks as Robert Langdon. In 2011, McGregor starred in the British comedy Salmon Fishing in the Yemen directed by Lasse Hallström and co-starring Emily Blunt and Kristin Scott Thomas, for which he received his second Golden Globe Award for Best Actor – Motion Picture Musical or Comedy nomination. That same year, he was awarded with the SIFF Golden Space Needle Award for Outstanding Achievement in Acting at the 2011 Seattle International Film Festival. In 2012, he was a member of the Jury for the Main Competition at the 2012 Cannes Film Festival.
Sources: en.wikipedia.org
==== Moisture passageways ==== The driving force of moisture movement is chemical potential. However, it is not always easy to relate chemical potential in wood to commonly observable variables, such as temperature and moisture content. Moisture in wood moves within the wood as liquid or vapour through several types of passageways, based on the nature of the driving force, (e.g. pressure or moisture gradient), and variations in wood structure, as explained in the next section on driving forces for moisture movement. These pathways consist of cavities of the vessels, fibres, ray cells, pit chambers and their pit membrane openings, intercellular spaces and transitory cell wall passageways. Movement of water takes place in these passageways in any direction, longitudinally in the cells, as well as laterally from cell to cell until it reaches the lateral drying surfaces of the wood. The higher longitudinal permeability of sapwood of hardwood is generally caused by the presence of vessels. The lateral permeability and transverse flow is often very low in hardwoods. The vessels in hardwoods are sometimes blocked by the presence of tyloses and/or by secreting gums and resins in some other species, as mentioned earlier. The presence of gum veins, the formation of which is often a result of natural protective response of trees to injury, is commonly observed on the surface of sawn boards of most eucalypts.
== Career == Zaffaroni joined Syntex, then a small chemical company in Mexico, as a biochemist in 1951. He participated in turning Syntex into a major multinational pharmaceutical company, moving it to Palo Alto, California. He was appointed president of the U.S. subsidiary in 1962. In 1968, he founded ALZA, a syllabic abbreviation of his name, to develop medical treatments through controlled drug delivery. He modeled new delivery systems after the processes discovered in endocrinology – where glands deliver very small amounts of hormones but have a tremendous effect –. ALZA's first controlled drug delivery product was used to treat glaucoma. Other products that incorporated Zaffaroni's drug delivery technologies include Glucotrol, for non insulin-dependent diabetes; Duragesic, for management of severe chronic pain; NicoDerm CQ, for smoking cessation; and Transderm-Scop, to prevent nausea and vomiting associated with motion sickness. In 1980, Zaffaroni established DNAX, a developer of macromolecular products that combines the technologies of genetic engineering and immunobiology. In 1988 he co-founded Affymax, specializing in combinatorial chemistry to reduce the cost and time of identifying new medicines. In 1991 he co-founded Affymetrix, specializing in using genetics for developing new medicine. He was also involved in the creation of Perlegen Sciences, an Affymetrix spin-off which works on finding genetic causes of disease. In 1994, he founded Symyx Technologies, a company dedicated to utilizing combinatorial chemistry technologies.
=== Media === The Spectator opined that "In any discipline, we seek only to discover who is the fastest, or the strongest, the most accurate or the most coordinated. What's absolutely crucial, at least as far as retaining spectator interest goes, is that the advantage is natural." The Daily Telegraph's sports writer commented that "Remarkably it seems a more fleshed-out idea than the European Super League". Cyclist wondered who would be willing to sponsor the event, noting that as of late July 2023, no sponsors were mentioned on TEG's website. Writing for The Globe and Mail, Alex Cyr said, "I will admit, I am incredibly curious to see an 'enhanced' person running faster than Usain Bolt, or swimming better than Michael Phelps. But I would not want to be that person, and I bet that neither will the serious athletes who have so far managed to avoid doping infractions." The Independent said that while the sporting world has been mostly dismissive, "D'Souza is intelligent and well-connected, and he has brought down big targets before. So when he says it's going to happen, he is deadly serious." The Sydney Morning Herald's sport columnist said that "the Enhanced Games are a dangerous, iniquitous concept." Outsports criticized D'Souza's use of LGBTQ language like "coming out" to describe athletes openly using performance-enhancing drugs. D'Souza is an out gay man. OutKick's writer said in February 2025 "Humans LOVE modern gladiators accomplishing feats that none of us ever could. The Olympics can still have non-tainted records ...
Circumcision is near-universal among Jews. The mitzvah of circumcision on the eighth day of life is considered among the most important commandments in Judaism. Barring extraordinary circumstances, failure to undergo the rite is seen by followers of Judaism as leading to a state of Kareth: the extinction of the soul and denial of a share in the world to come. Reasons for biblical circumcision include to show off "patrilineal descent, sexual fertility, male initiation, cleansing of birth impurity, and dedication to God".
Ganapati (2008) defines these categories as the following:In Tenure co-operatives, members collectively own and manage housing, similar to co-operative housing in the Western countries. Finance co-operatives provide loans for new construction or housing repairs to members. Building co-operatives construct housing for their members, but they may also be involved in land development.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.